Global SRS Treatment Services Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

SRS Treatment Services Market Size

• The global SRS treatment services market size was valued at USD 6.2 billion in 2025and is expected to reach USD 11.06 billion by 2033, at a CAGR of7.5% during the forecast period
• Growth is driven by increasing demand for minimally invasive and precision-guided treatment procedures, as stereotactic radiosurgery enables targeted therapy with reduced complications, shorter hospital stays, and improved patient outcomes, making it highly preferred in modern oncology and neurosurgical care
• Rising adoption of outpatient and day-care radiotherapy services, especially in cancer treatment centers and hospitals, is accelerating market expansion, as healthcare providers focus on cost-effective treatment delivery and improved patient convenience through shorter treatment cycles

SRS Treatment Services Market Analysis

• SRS treatment services, which provide highly precise, non-invasive radiation therapy procedures for treating brain tumors, spinal lesions, and other complex cancers, are becoming essential components in modern oncology and neurosurgical care due to their ability to deliver targeted treatment while minimizing damage to surrounding healthy tissues
• The escalating demand for SRS treatment services is primarily driven by the increasing global burden of cancer, rising preference for outpatient and minimally invasive procedures, and growing adoption of precision oncology approaches, along with continuous advancements in imaging, robotics, and AI-driven treatment planning technologies that enhance clinical outcomes and operational efficiency
• North America dominated the SRS treatment services market with the largest revenue share of approximately 43.6% in 2024, supported by advanced healthcare infrastructure, strong reimbursement frameworks, and high adoption of stereotactic radiosurgery procedures across specialized cancer centers
• Asia-Pacific is expected to be the fastest growing region in the SRS treatment services market during the forecast period due to rapidly increasing cancer incidence, expanding healthcare infrastructure, rising government investments in oncology care, and growing number of radiotherapy centers across countries such as China, India, and South Korea
• The stereotactic radiosurgery (SRS) procedure segment dominated the SRS treatment services market with a market share of approximately 48.4% in 2024, driven by its widespread use in treating brain metastases, neurological disorders, and localized tumors due to its high precision, shorter treatment duration, and improved patient outcomes

Report Scope and SRS Treatment Services Market Segmentation

SRS Treatment Services Market Trends

“Growing Adoption of Minimally Invasive and Precision Oncology Treatments”

• A significant and accelerating trend in the global SRS treatment services market is the increasing shift toward minimally invasive, high-precision treatment approaches that enhance clinical outcomes while reducing patient recovery time and hospital stays across oncology and neurosurgical applications
• For instance, healthcare providers are increasingly adopting advanced stereotactic radiosurgery techniques integrated with real-time imaging and robotic delivery systems to improve targeting accuracy and treatment effectiveness
• Technological advancements in imaging modalities, robotics, and AI-driven treatment planning are enabling the development of SRS treatment services with improved precision, faster treatment delivery, and enhanced patient safety, helping healthcare providers optimize clinical workflows
• The increasing adoption of outpatient and day-care treatment models is supporting the demand for SRS treatment services that improve patient convenience, reduce hospitalization costs, and enhance treatment accessibility
• This trend toward precision-driven and patient-centric treatment solutions is reshaping industry expectations for clinical quality, operational efficiency, and patient outcomes across hospitals and specialized cancer treatment centers
• The demand for advanced SRS treatment services with improved accuracy, reduced side effects, and shorter treatment cycles is growing rapidly across both developed and emerging healthcare markets, driven by increasing cancer prevalence and technological advancements
• Increasing integration of digital health technologies and data-driven treatment approaches is gaining traction due to the rising need for personalized treatment planning and improved decision-making in oncology care

SRS Treatment Services Market Dynamics

Driver

“Rising Demand for Precision and Non-Invasive Cancer Treatment”

• The increasing demand for non-invasive and highly precise cancer treatment solutions, coupled with the rising global burden of cancer and neurological disorders, is a major driver fueling the growth of the SRS treatment services market globally
• For instance, healthcare systems in regions such as North America and Europe are encouraging the adoption of advanced radiotherapy services to improve treatment outcomes and reduce patient recovery time
• As healthcare providers focus more on improving clinical accuracy and efficiency, SRS treatment services offer targeted tumor treatment with minimal damage to surrounding healthy tissues, improving overall treatment effectiveness compared to conventional surgical procedures
• Furthermore, the growing shift toward personalized medicine and precision oncology, supported by technological advancements and increasing healthcare investments, is driving the adoption of SRS treatment services across healthcare facilities
• The versatility of these services across applications such as brain tumor treatment, spine radiosurgery, and stereotactic body radiotherapy is driving widespread adoption in modern oncology practices
• Expanding healthcare infrastructure and rising healthcare expenditure in emerging economies are further supporting market expansion through increased access to advanced cancer treatment services
• Government initiatives and healthcare policies promoting advanced cancer care and digital health integration are accelerating investments and adoption of SRS treatment services globally

Restraint/Challenge

“High Cost of Treatment and Limited Accessibility”

• Challenges related to the high cost of SRS treatment services and limited availability of advanced radiotherapy infrastructure pose significant barriers to large-scale adoption, particularly in developing regions
• For instance, the implementation of SRS treatment services requires substantial investment in advanced equipment, specialized facilities, and skilled professionals, which can limit accessibility in cost-sensitive healthcare systems
• Addressing these challenges through cost optimization, expansion of healthcare infrastructure, and increasing public-private investments is critical for improving market penetration
• While demand for advanced cancer treatment services is increasing, limitations related to availability of trained professionals and complex treatment workflows can restrict service adoption in certain regions
• Overcoming these challenges through continuous technological innovation, training programs, and expansion of oncology care facilities will be essential for long-term market growth
• Stringent regulatory requirements and reimbursement limitations can also increase operational complexity and affect service affordability, potentially impacting overall market adoption

SRS Treatment Services Market Scope

The market is segmented on the basis of product, source, form, and application.

• By Procedure Type

On the basis of procedure type, the global SRS treatment services market is segmented into stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), fractionated stereotactic radiotherapy (FSRT), and deep brain stimulation. The stereotactic radiosurgery segment dominated the market with the largest revenue share of approximately 48.4% in 2024, driven by its extensive use in treating brain tumors, metastases, and neurological disorders due to its high precision, non-invasive nature, and shorter treatment duration. SRS is widely preferred as an alternative to conventional surgery, supported by its ability to deliver targeted radiation with minimal damage to surrounding tissues. Its increasing adoption across oncology and neurosurgical applications, along with continuous advancements in imaging and treatment delivery, is further strengthening segment dominance globally.

The fractionated stereotactic radiotherapy segment is expected to witness the fastest growth during the forecast period, fueled by rising demand for treatments requiring multiple sessions for improved safety and effectiveness in complex tumors. Increasing adoption in cases where single-dose SRS is not suitable and advancements in treatment planning and delivery technologies are further accelerating segment growth globally.

• By Technology Platform

On the basis of technology platform, the market is segmented into linear accelerator (LINAC)-based systems, Gamma Knife systems, CyberKnife systems, proton therapy systems, and MRI-guided radiosurgery systems. The LINAC-based systems segment dominated the market with the largest revenue share of approximately 37.5% in 2024, driven by its widespread availability, cost-effectiveness, and ability to treat a wide range of tumor types across different anatomical sites. These systems are extensively used in hospitals and cancer treatment centers due to their flexibility and integration with advanced treatment planning solutions.

The MRI-guided radiosurgery systems segment is expected to witness the fastest growth during the forecast period, fueled by increasing demand for real-time imaging and adaptive treatment capabilities. Technological advancements enabling precise tumor tracking and treatment adjustment during therapy are significantly enhancing clinical outcomes and driving segment growth globally

• By Application

On the basis of application, the market is segmented into brain tumors, lung cancer, spine tumors, prostate cancer, arteriovenous malformations, trigeminal neuralgia, and other neurological disorders. The brain tumor segment dominated the market with the largest revenue share of approximately 42.6% in 2024, driven by the high prevalence of brain metastases and the widespread adoption of stereotactic radiosurgery as a standard treatment option. The ability to deliver precise radiation to intracranial targets while preserving surrounding healthy tissue is supporting strong segment demand.

The lung cancer segment is expected to witness the fastest growth during the forecast period, fueled by increasing global incidence of lung cancer and rising adoption of stereotactic body radiotherapy for early-stage tumors. Advancements in motion management and imaging technologies are further supporting segment expansion globally.

• By End User

On the basis of end user, the market is segmented into hospitals, cancer treatment centers, ambulatory surgical centers, and specialty clinics. The hospitals segment dominated the market with the largest revenue share of approximately 46.8% in 2024, driven by high patient volume, availability of advanced radiotherapy infrastructure, and integration of multidisciplinary oncology services. Hospitals are the primary centers for delivering complex radiotherapy treatments, supporting their dominant position in the market.

The cancer treatment centers segment is expected to witness the fastest growth during the forecast period, fueled by increasing specialization in oncology care, expansion of dedicated radiotherapy facilities, and rising demand for advanced and efficient treatment services.

SRS Treatment Services Market Regional Analysis

• North America dominated the SRS treatment services market with the largest revenue share of approximately 43.6% in 2024, supported by advanced healthcare infrastructure, strong reimbursement frameworks, and high adoption of stereotactic radiosurgery procedures across specialized oncology centers. The region benefits from the presence of well-established hospitals, increasing utilization of precision radiotherapy, and continuous technological advancements in treatment delivery systems, particularly in the United States and Canada
• Healthcare providers and service operators in the region place significant emphasis on advanced treatment technologies, integration of imaging and robotics in radiosurgery, and adoption of minimally invasive oncology procedures, leading to widespread utilization of SRS treatment services across hospitals and specialized cancer treatment centers. This strong market position is further supported by increasing healthcare expenditure, growing cancer prevalence, and continuous investments in oncology care infrastructure, establishing SRS treatment services as critical components in modern cancer treatment pathways

U.S. SRS Treatment Services Market Insight

The U.S. SRS treatment services market captured the largest revenue share within North America in 2024, driven by high adoption of advanced radiotherapy procedures, strong presence of specialized cancer treatment centers, and increasing demand for precision oncology solutions. The growing prevalence of cancer and neurological disorders, along with rising preference for minimally invasive treatment approaches, continues to drive market growth. Additionally, advancements in treatment planning and delivery technologies significantly contribute to sustained market expansion

Europe SRS Treatment Services Market Insight

The Europe SRS treatment services market is projected to expand at a steady CAGR throughout the forecast period, primarily driven by increasing adoption of advanced radiotherapy treatments and strong regulatory support for innovative cancer care solutions. Healthcare systems in the region emphasize high-quality treatment standards, patient safety, and integration of digital healthcare technologies, fostering consistent adoption of SRS treatment services across hospitals and oncology centers. Growth is further supported by rising investments in healthcare infrastructure and expanding access to advanced cancer treatment

U.K. SRS Treatment Services Market Insight

The U.K. SRS treatment services market is anticipated to grow at a notable CAGR during the forecast period, supported by increasing demand for advanced cancer treatment services and strong focus on improving patient outcomes. Expansion of radiotherapy services and growing adoption of minimally invasive procedures are driving demand across healthcare facilities. The country’s well-established healthcare system and ongoing investments in oncology infrastructure are accelerating the adoption of SRS treatment services

Germany SRS Treatment Services Market Insight

The Germany SRS treatment services market is expected to expand at a considerable CAGR during the forecast period, driven by strong focus on technological innovation and high adoption of advanced medical treatments. Germany’s emphasis on precision medicine, high-quality healthcare services, and integration of advanced radiotherapy technologies supports the widespread use of SRS treatment services. Increasing investments in research and development and strong healthcare infrastructure further contribute to market growth

Asia-Pacific SRS Treatment Services Market Insight

The Asia-Pacific SRS treatment services market is poised to grow at the fastest CAGR during the forecast period of 2026 to 2033, driven by increasing cancer incidence, improving healthcare infrastructure, and rising investments in advanced radiotherapy technologies. Countries such as China, India, and Japan play a key role in expanding access to cancer treatment services. Rising healthcare expenditure, growing awareness regarding advanced oncology treatments, and government initiatives to strengthen cancer care infrastructure are accelerating market growth across the region

Japan SRS Treatment Services Market Insight

The Japan SRS treatment services market is gaining momentum due to strong focus on advanced medical technologies and high-quality healthcare services. Increasing adoption of precision radiotherapy procedures and integration of advanced imaging technologies are driving demand. The country’s emphasis on innovation and technological advancement supports the development and expansion of SRS treatment services across healthcare facilities

India SRS Treatment Services Market Insight

The India SRS treatment services market accounted for a growing share in Asia-Pacific in 2024, attributed to increasing cancer prevalence, expanding healthcare infrastructure, and rising investments in oncology care. Growing awareness regarding advanced treatment options and increasing adoption of radiotherapy services are driving demand. Government initiatives aimed at improving cancer care facilities and expanding access to advanced treatment technologies are key factors supporting sustained market growth in India

SRS Treatment Services Market Share

The SRS Treatment Services industry is primarily led by well-established companies, including:

• Elekta AB (Sweden)
• Varian Medical Systems (U.S.)
• Accuray Incorporated (U.S.)
• Brainlab AG (Germany)
• Siemens Healthineers (Germany)
• GE HealthCare Technologies Inc. (U.S.)
• Philips Healthcare (Netherlands)
• IBA Worldwide (Belgium)
• Mevion Medical Systems (U.S.)
• ViewRay Technologies, Inc. (U.S.)
• Panacea Medical Technologies Pvt. Ltd. (India)
• GenesisCare (Australia)
• HCA Healthcare (U.S.)
• Mayo Clinic (U.S.)
• Cleveland Clinic (U.S.)
• Apollo Hospitals Enterprise Ltd. (India)
• Fortis Healthcare Limited (India)
• Manipal Hospitals (India)
• Ramsay Health Care (Australia)
• Fresenius SE & Co. KGaA (Germany)

What are the Recent Developments in Global SRS Treatment Services Market?

• In December 2025, GenesisCare expanded its SRS treatment services by enhancing its stereotactic radiosurgery capabilities across key oncology centers, aimed at improving access to precision cancer treatment and reducing patient treatment time
• In October 2025, HCA Healthcare strengthened its SRS treatment services by expanding advanced radiotherapy programs across its hospital network, focusing on improving patient outcomes through minimally invasive cancer treatment solutions
• In August 2025, Apollo Hospitals Enterprise Ltd. expanded its SRS treatment services by introducing advanced radiosurgery technologies in its oncology centers, aimed at enhancing treatment accuracy and accessibility in India
• In June 2025, Fortis Healthcare Limited enhanced its SRS treatment services portfolio by upgrading radiotherapy infrastructure with advanced stereotactic treatment capabilities to improve precision and efficiency in cancer treatment
• In March 2024, Mayo Clinic expanded its SRS treatment services by advancing the use of image-guided and robotic radiosurgery techniques, aimed at improving targeting precision and clinical outcomes in complex tumor treatments

SKU-76211